GSK slashes workforce

In another move to encourage innovation while trimming its research and development budget, pharmaceutical company GlaxoSmithKline has announced that it will cut two percent, or 350 jobs, from its global R&D staff, according to linkurl:__The Wall Street Journal__.;http://online.wsj.com/article/SB121318410957563897.html?mod=hps_us_at_glance_health "These changes are part of GSK's longer-term strategy to ensure that we invest in key areas of future growth and evolve our business to compete effect

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.


Learn about our editorial policies.

Jun 10, 2008
In another move to encourage innovation while trimming its research and development budget, pharmaceutical company GlaxoSmithKline has announced that it will cut two percent, or 350 jobs, from its global R&D staff, according to linkurl:__The Wall Street Journal__.;http://online.wsj.com/article/SB121318410957563897.html?mod=hps_us_at_glance_health "These changes are part of GSK's longer-term strategy to ensure that we invest in key areas of future growth and evolve our business to compete effectively in what is a rapidly changing and challenging environment for pharmaceutical companies," a GSK spokesman told __The Wall Street Journal__. This news comes on the heels of an linkurl:announcement;http://www.the-scientist.com/blog/display/54738/ from GSK that it will be "more biotech-like," providing incentives and disincentives to researchers searching for marketable drug discoveries. Three GSK research labs, in the U.S., Britain and Italy, will be affected by the cuts, which are part of a GSK plan to save 1.37 billion a year by 2010.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?